ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis.

European radiology ·Vol. 17 ·No. 10 ·2007-10-00 ·Pages 2692-6

Thomsen HS, European Society of Urogenital Radiology ESUR

Abstract

暂无摘要

MeSH Terms

Chemical and Drug Induced Liver Injury/etiology,prevention & control Contrast Media/adverse effects Fibrosis/chemically induced,prevention & control Gadolinium/adverse effects Humans Renal Dialysis Skin Diseases/chemically induced

Chemicals

Contrast Media Gadolinium

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Thomsen Henrik S

Department of Diagnostic Radiology, Copenhagen University Hospital, Herlev, Denmark. [email protected]

European Society of Urogenital Radiology (ESUR)

References (14)

14 references, click to expand

Gadolinium-containing contrast media for radiographic examinations: a position paper.
Eur Radiol. 2002 Oct;12(10):2600-5 PMID: 12271402
Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide.
Eur Radiol. 2006 Dec;16(12):2619-21 PMID: 17061066
In which patients should serum creatinine be measured before iodinated contrast medium administration?
Eur Radiol. 2005 Apr;15(4):749-54 PMID: 15627181
Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
Nephrol Dial Transplant. 2006 Apr;21(4):1104-8 PMID: 16431890
Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006.
MMWR Morb Mortal Wkly Rep. 2007 Feb 23;56(7):137-41 PMID: 17318112
Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?
Br J Radiol. 2007 Feb;80(950):73-6 PMID: 17392401
Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
Clin J Am Soc Nephrol. 2007 Mar;2(2):264-7 PMID: 17699423
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.
J Am Acad Dermatol. 2007 Jan;56(1):21-6 PMID: 17097388
Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update.
Am J Transplant. 2006 Sep;6(9):2212-7 PMID: 16780542
Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
AJR Am J Roentgenol. 2007 Feb;188(2):586-92 PMID: 17242272
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
J Am Soc Nephrol. 2006 Sep;17(9):2359-62 PMID: 16885403
Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).
Invest Radiol. 2007 Feb;42(2):139-45 PMID: 17220732
Nephrogenic systemic fibrosis: risk factors and incidence estimation.
Radiology. 2007 Apr;243(1):148-57 PMID: 17267695
Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.
Fundam Clin Pharmacol. 2006 Dec;20(6):563-76 PMID: 17109649

Article Info

Journal

European radiology

Abbr.

Eur Radiol

ISSN

0938-7994

DOI

10.1007/s00330-007-0744-5

[email protected]

Published

2007-10-00

Pages

2692-6

Language

English

Region

Germany

NLM ID

9114774

Subset

External Links

PubMed source DOI: 10.1007/s00330-007-0744-5 View journal details

Analysis Services

ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis.

Contact

WeChat Official Account